ImmuPharma Competitors
| IMM Stock | 1.19 0.24 16.78% |
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of ImmuPharma PLC competition on your existing holdings.
ImmuPharma |
ImmuPharma PLC Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between ImmuPharma PLC and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of ImmuPharma and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of ImmuPharma PLC does not affect the price movement of the other competitor.
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between ImmuPharma Stock performing well and ImmuPharma PLC Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze ImmuPharma PLC's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 0JUJ | 1.11 | 0.25 | 0.09 | (0.87) | 0.85 | 3.09 | 5.29 | |||
| FUM | 2.09 | 0.08 | (0.03) | (0.31) | 2.32 | 3.73 | 26.57 | |||
| 0JVD | 1.20 | 0.53 | 0.39 | 6.85 | 0.44 | 2.86 | 9.17 | |||
| DAL | 1.30 | (0.02) | (0.03) | 0.08 | 1.89 | 4.44 | 10.18 | |||
| 0QUS | 1.45 | (0.02) | (0.02) | 0.11 | 1.51 | 3.38 | 11.94 | |||
| 0YTR | 1.11 | 0.32 | 0.22 | 1.15 | 0.70 | 2.72 | 12.36 | |||
| 0JZZ | 2.64 | 0.09 | (0.03) | (0.07) | 2.89 | 5.34 | 25.45 |
Cross Equities Net Income Analysis
Compare ImmuPharma PLC and related stocks such as Liberty Media Corp, Futura Medical, and Live Nation Entertainment Net Income Over Time
| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0JUJ | 584 M | 584 M | 584 M | 584 M | (29 M) | 64 M | 329 M | 255 M | (150 M) | (311 M) | (596 M) | (190 M) | 558 M | 185 M | 194.2 M |
| FUM | (372 K) | (1.8 M) | (2.2 M) | (2.2 M) | (3 M) | (5.1 M) | (3.7 M) | (3.9 M) | (5.9 M) | (8.9 M) | (2.4 M) | (5 M) | (5.8 M) | (6.5 M) | (6.2 M) |
| 0JVD | (164 M) | (164 M) | (164 M) | (43.9 M) | (96.5 M) | (65.7 M) | (47 M) | (97.6 M) | (17.7 M) | (4.9 M) | (1.7 B) | (670.7 M) | 149.2 M | 315.8 M | 331.6 M |
| DAL | (3.1 M) | (3.1 M) | (2 M) | (577 K) | 3.5 M | 21.6 M | 34.9 M | 68.3 M | 75.2 M | 78.2 M | (100.7 M) | (6.3 M) | 96.7 M | 90.2 M | 94.7 M |
| 0QUS | (1.2 M) | 14.1 M | 22.2 M | (11.7 M) | 6.8 M | 15.3 M | 33.2 M | 89.3 M | 128.8 M | 45 M | 167.3 M | 198.2 M | 66.9 M | 127.6 M | 66.7 M |
| 0JZZ | 71.8 M | 71.8 M | 71.8 M | 88.3 M | 49.6 M | 137.3 M | 219.1 M | 293.9 M | 1 B | 373.8 M | 463.3 M | 730.9 M | 959.7 M | (556.5 M) | (528.7 M) |
ImmuPharma PLC and related stocks such as Liberty Media Corp, Futura Medical, and Live Nation Entertainment Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in ImmuPharma PLC financial statement analysis. It represents the amount of money remaining after all of ImmuPharma PLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.ImmuPharma PLC Competitive Analysis
The better you understand ImmuPharma PLC competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, ImmuPharma PLC's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across ImmuPharma PLC's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
ImmuPharma PLC Competition Performance Charts
Five steps to successful analysis of ImmuPharma PLC Competition
ImmuPharma PLC's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by ImmuPharma PLC in relation to its competition. ImmuPharma PLC's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of ImmuPharma PLC in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact ImmuPharma PLC's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to ImmuPharma PLC, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your ImmuPharma PLC position
In addition to having ImmuPharma PLC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Broad Commodities ETFs Thematic Idea Now
Broad Commodities ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Commodities ETFs theme has 26 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Commodities ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in ImmuPharma Stock
ImmuPharma PLC financial ratios help investors to determine whether ImmuPharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImmuPharma with respect to the benefits of owning ImmuPharma PLC security.